GSA Capital Partners’s Stoke Therapeutics STOK Stock Holding History
Bought
Maintained
Sold
Other funds holding STOK
RI
LCM
RG
BBA
BI
GSA Capital Partners's STOK Position: Q1 2026 in Review
GSA Capital Partners sold out of Stoke Therapeutics (STOK) in Q1 2026, closing a stake of 7,076 shares — an estimated $225K sold.
GSA Capital Partners first reported a position in STOK in Q3 2021 and held it in 13 quarters. The position peaked at $1.37M in Q3 2023. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.
- GSA Capital Partners reported no remaining Stoke Therapeutics position as of Q1 2026 after selling out during the quarter.
- GSA Capital Partners sold 7,076 Stoke Therapeutics shares in Q1 2026, an estimated $225K.
- GSA Capital Partners first reported a position in Stoke Therapeutics in Q3 2021 and held it in 13 quarters.
- GSA Capital Partners's Stoke Therapeutics position peaked at $1.37M in Q3 2023.
- 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.
Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.